243 related articles for article (PubMed ID: 37973622)
41. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
42. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
43. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.
Sugitani I; Onoda N; Ito KI; Suzuki S
J Nippon Med Sch; 2018; 85(1):18-27. PubMed ID: 29540641
[TBL] [Abstract][Full Text] [Related]
44. Management of the compromised airway and role of tracheotomy in anaplastic thyroid carcinoma.
Mani N; McNamara K; Lowe N; Loughran S; Yap BK
Head Neck; 2016 Jan; 38(1):85-8. PubMed ID: 25215461
[TBL] [Abstract][Full Text] [Related]
45. [Anaplastic thyroid carcinoma : new therapeutic approaches].
Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
[TBL] [Abstract][Full Text] [Related]
46. Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer: A Single-Institution 21-Year Experience.
Wu SS; Lamarre ED; Yalamanchali A; Brauer PR; Hong H; Reddy CA; Yilmaz E; Woody N; Ku JA; Prendes B; Burkey B; Nasr C; Skugor M; Heiden K; Chute DJ; Knauf JA; Campbell SR; Koyfman SA; Geiger JL; Scharpf J
JAMA Otolaryngol Head Neck Surg; 2023 Apr; 149(4):300-309. PubMed ID: 36757708
[TBL] [Abstract][Full Text] [Related]
47. Survival and prognostic factors of anaplastic thyroid carcinoma.
Paunovic IR; Sipetic SB; Zoric GV; Diklic AD; Savic DV; Marinkovic J; Zivaljevic VR
Acta Chir Belg; 2015; 115():62-7. PubMed ID: 26021793
[TBL] [Abstract][Full Text] [Related]
48. The role of targeted therapy and/or immunotherapy therapy in anaplastic thyroid carcinoma.
Wu G; Song Y; Yang S; Li H; Liu S; Gui L; Ni S
Endocrine; 2024 Jun; 84(3):1013-1020. PubMed ID: 38146047
[TBL] [Abstract][Full Text] [Related]
49. Coexisting Papillary and Anaplastic Thyroid Cancer: Elucidating the Spectrum of Aggressive Behavior.
Greenberg JA; Moore MD; Thiesmeyer JW; Egan CE; Lee YJ; Christos P; Zarnegar R; Beninato T; Fahey Iii TJ; Finnerty BM
Ann Surg Oncol; 2023 Jan; 30(1):137-145. PubMed ID: 36224511
[TBL] [Abstract][Full Text] [Related]
50. Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.
Yoshida A; Sugino K; Sugitani I; Miyauchi A
World J Surg; 2014 Sep; 38(9):2311-6. PubMed ID: 24687351
[TBL] [Abstract][Full Text] [Related]
51. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
52. Anaplastic Thyroid Cancer: A Rare Entity Presented Clinically Only with Fever and Elevated CRP.
Garmpis N; Damaskos C; Garmpi A; Liakea A; Mantas D
Chirurgia (Bucur); 2019; 114(5):659-663. PubMed ID: 31670642
[TBL] [Abstract][Full Text] [Related]
53. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.
Silver Karcioglu A; Iwata AJ; Pusztaszeri M; Abdelhamid Ahmed AH; Randolph GW
Cancer Cytopathol; 2022 Mar; 130(3):174-180. PubMed ID: 34618407
[No Abstract] [Full Text] [Related]
54. New Perspectives Regarding Anaplastic Thyroid Carcinoma Approach Improvement.
Figueiredo AS; Andrea-Ferreira P
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):555-564. PubMed ID: 29886838
[TBL] [Abstract][Full Text] [Related]
55. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).
Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H
Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656
[TBL] [Abstract][Full Text] [Related]
56. The value of multimodal treatment in anaplastic thyroid cancer patients with distant metastasis.
Guo H; Lin H
BMC Surg; 2024 Mar; 24(1):79. PubMed ID: 38438944
[TBL] [Abstract][Full Text] [Related]
57. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case.
Juhlin CC; Höög A
Int J Surg Pathol; 2019 Sep; 27(6):658-663. PubMed ID: 30931661
[TBL] [Abstract][Full Text] [Related]
58. BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation.
Wang X; Ying T; Yuan J; Wang Y; Su X; Chen S; Zhao Y; Zhao Y; Sheng J; Teng L; Luo C; Wang W
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184950
[TBL] [Abstract][Full Text] [Related]
59. [Re-understanding of the biological behavior of anaplastic thyroid carcinoma].
Zhou YK; Shi BY
Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(5):375-377. PubMed ID: 36740397
[TBL] [Abstract][Full Text] [Related]
60. Chemoradiation in anaplastic thyroid carcinomas.
Sun XS; Sun SR; Guevara N; Fakhry N; Marcy PY; Lassalle S; Peyrottes I; Bensadoun RJ; Lacout A; Santini J; Cals L; Bosset JF; Garden AS; Thariat J
Crit Rev Oncol Hematol; 2013 Jun; 86(3):290-301. PubMed ID: 23218594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
